IA
VKTX icon

Inspire Advisors’s Viking Therapeutics VKTX Stock Holding History

Inspire Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Sell
5,391
-4,042
-43% -$131K 0.01% 678
2026
Q1 		$307K Sell
9,433
-1,468
-13% -$47.2K 0.03% 461
2025
Q4 		$384K Sell
10,901
-11,714
-52% -$415K 0.04% 369
2025
Q3 		$594K Buy
+22,615
New +$675K 0.06% 271

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Inspire Advisors's VKTX Position: Q2 2026 in Review

Inspire Advisors reduced its Viking Therapeutics (VKTX) stake by 43% in Q2 2026, selling an estimated $131K and leaving 5,391 shares worth $210K. The position accounts for 0.01% of the portfolio, ranked #678.

Inspire Advisors first reported a position in VKTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $594K in Q3 2025. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Inspire Advisors held 5,391 shares of Viking Therapeutics worth $210K as of Q2 2026.
  • Inspire Advisors sold 4,042 Viking Therapeutics shares in Q2 2026, an estimated $131K.
  • Viking Therapeutics made up 0.01% of Inspire Advisors's portfolio in Q2 2026, its #678 holding.
  • Inspire Advisors first reported a position in Viking Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Inspire Advisors's Viking Therapeutics position peaked at $594K in Q3 2025.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Inspire Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.